FDA clears low-level laser therapy device for nail fungus

The FDA has approved Erchonia's Lunula laser device, which provides low-level laser therapy to treat nail fungus.

Content Dam Bow Online Articles 2016 07 385718 Web

The FDA has approved Erchonia (McKinney, TX)'s Lunula laser device, which provides low-level laser therapy to treat nail fungus.

The device increases the amount of clear nail in patients infected with onychomycosis (nail fungus)—in the clinical trial for the device, 67% of patients met the success criteria of 3 mm of clear nail growth. By six months after the initial treatment, the patients averaged more than 5 mm of new growth.

Content Dam Bow Online Articles 2016 07 385718 Web

Previously, treatment for nail fungus included prescription oral antifungal medication, which increased potential for liver toxicity issues, or else called for ineffective, over-the-counter topical creams.

The portable device applies a laser to the infected area. During the study, patients between 18 and 70 years old received treatments once a week for four weeks. Prior to FDA approval, the device went through four clinical trials, which recorded no known side effects.

For more information, please visit www.erchonia.com.

More in Biophotonics Tools